You can literally freeze off fat cells — here's how CoolSculpting works

CoolSculpting freezes off stubborn fat through a procedure called cryolipolysis. Each treatment costs between $650 and $800.
TCTMD

HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease

Sotatercept-csrk (Winrevair; Merck Sharp & Dohme) added on top of standard therapies improves outcomes in patients who are less than a year out from a diagnosis of pulmonary arterial hypertension (PAH ...
Healio

Add-on Winrevair lowers clinical worsening risk in recently diagnosed PAH

Please provide your email address to receive an email when new articles are posted on . Fewer adults diagnosed with PAH less than 1 year ago receiving add-on Winrevair vs. placebo had at least one ...
FiercePharma

Merck unveils data from 2nd Winrevair PAH study previously halted for efficacy

Two clinical trials of Merck’s pulmonary arterial hypertension (PAH) drug Winrevair were so conclusive that the studies were halted within the last year because the efficacy of the treatment was ...
HealthDay on MSN

Sotatercept Reduces Risk for Clinical Worsening in Adults With Recently Diagnosed PAH

The addition of sotatercept, an activin-signaling inhibitor, to background therapy results in a lower risk for clinical worsening among adults with pulmonary arterial hypertension (PAH) who were ...
Yahoo Finance

WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase ...

RAHWAY, N.J., September 30, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating ...
The New England Journal of Medicine

Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis

Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...
PharmiWeb

AliveGen Presents Preclinical Data Showing ALG-801 Outperforms Standard Therapies in Pulmonary Arterial Hypertension Model

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--AliveGen USA Inc. (AliveGen), a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating that its investigational therapy ...
The Globe and Mail

WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in ...
Medical Xpress

Biologic drug reduces symptoms and hospitalization for severe pulmonary hypertension after diagnosis in clinical trial

Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within ...
MedPage Today

Drug Delays Worsening of Newly Diagnosed Pulmonary Arterial Hypertension

For recently diagnosed pulmonary arterial hypertension (PAH), adding sotatercept (Winrevair) to standard care lowered the risk of clinical worsening, the randomized HYPERION trial showed. Among 320 ...